- Home
- ADV vs AUPH Comparison
ADV vs AUPH Comparison
Compare ADV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | AUPH |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ADV | AUPH |
|---|---|---|
| Price | $0.84 | $15.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $17.25 |
| AVG Volume (30 Days) | 602.3K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $3,502,796,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.22 |
| Revenue Next Year | $0.96 | $15.40 |
| P/E Ratio | ★ N/A | $28.81 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $0.83 | $6.55 |
| 52 Week High | $3.48 | $16.48 |
Technical Indicators
Market Signals| Indicator | ADV | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 57.76 |
| Support Level | $0.83 | $15.15 |
| Resistance Level | $0.98 | $16.03 |
| Average True Range (ATR) | 0.07 | 0.50 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 4.63 | 57.02 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.